News und Analysen
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
EQS-News: Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
EQS-News: Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division
The Consumer Health division of Bayer has selected Interpublic Group (NYSE: IPG) as the global agency partner for all creative, production and media, responsible for marketing activities for some
Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s Annual Scientific
EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
EQS-News: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-News: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of
EQS-News: Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
EQS-News: Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
EQS-News: Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
EQS-News: Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
EQS-Adhoc: FamiCord AG: Polski Bank Komórek Macierzystych sp. z o. o. is to acquire 100 % in stem cell bank “nOvum” spółka z ograniczoną odpowiedzialnością, Warsaw, Poland
EQS-Adhoc: FamiCord AG: Polski Bank Komórek Macierzystych sp. z o. o. is to acquire 100 % in stem cell bank “nOvum” spółka z ograniczoną odpowiedzialnością, Warsaw, Poland
EQS-News: MPH Health Care AG publishes figures for the first half-year of 2025: Equity (NAV) amounts to EUR 205.1 million, which corresponds to EUR 47.91 per share. The equity ratio fell slightly to 93.7%
EQS-News: MPH Health Care AG publishes figures for the first half-year of 2025: Equity (NAV) amounts to EUR 205.1 million, which corresponds to EUR 47.91 per share. The equity ratio fell slightly to 93.7%
EQS-News: Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%
EQS-News: Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%
EQS-News: M1 Kliniken AG: Successful First Half of 2025 with EBIT Growth of 24% and Earnings per Share of EUR 0.63
EQS-News: M1 Kliniken AG: Successful First Half of 2025 with EBIT Growth of 24% and Earnings per Share of EUR 0.63
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
EQS-News: BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business
EQS-News: BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business
EQS-Adhoc: MAQUET Medical Systems AG submitted specified squeeze-out request and has determined cash compensation for minority shareholders of Pulsion Medical Systems SE to be EUR 20.57
EQS-Adhoc: MAQUET Medical Systems AG submitted specified squeeze-out request and has determined cash compensation for minority shareholders of Pulsion Medical Systems SE to be EUR 20.57
EQS-News: BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts
EQS-News: BRAIN Biotech reports dynamic Q3 revenue growth in core segment BRAINBiocatalysts
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
Gadoquatrane New Drug Application Accepted for Review by U.S. FDA
Bayer today announced that a New Drug Application (NDA) for its investigational contrast agent gadoquatrane has been accepted for review by the U.S. Food and Drug Administration (FDA). The NDA for
EQS-News: FamiCord AG significantly increases revenue and earnings in the first half of 2025 and shifts focus even more strongly to core business in the future
EQS-News: FamiCord AG significantly increases revenue and earnings in the first half of 2025 and shifts focus even more strongly to core business in the future
EQS-News: Corbion and BRAIN Biotech team to shape the future of innovation in nature-based ingredient technologies
EQS-News: Corbion and BRAIN Biotech team to shape the future of innovation in nature-based ingredient technologies
EQS-Adhoc: MeVis Medical Solutions AG: Forecast adjustment for the 2024/2025 fiscal year
EQS-Adhoc: MeVis Medical Solutions AG: Forecast adjustment for the 2024/2025 fiscal year
Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center
Monsanto has now reached agreements in principle to resolve all Sky Valley Education Center cases, representing more than 200 plaintiffs overall, with the exception of the prior adverse verdicts
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
Bayer’s Aspirina, the #1 pain relief option in Mexico1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic